Robert Devenyi, MD, FRCSC, FACS
Professor and Chief of OphthalmologyUniversity of Toronto
Robert Devenyi, MD, MBA, FRCSC, FACS, is a Professor of Ophthalmology and Vision Sciences at The University of Toronto, Canada. He is the Director of the Donald K. Johnson Eye Center, Director of Retinal Services at University Health Network and Ophthalmologist-in-Chief at the University Health Network, The University of Toronto. He is also the Team Ophthalmologist for The Toronto Maple Leafs. He has experience in all aspects of adult and pediatric vitreoretinal surgery, anti-VEGF agents, and rheopheresis, and has also been a consultant in this field. Dr. Devenyi is also a member of the Clinical Studies Resource Centre of Toronto Western Research Institute. His research focuses on the development of a novel treatment for neovascular age-related macular degeneration, involving ultra high speed indocyanine angiography and a coupled diode laser, the surgical repair of complex retinal detachments, diabetic retinopathy, and all aspects of macular degeneration. (This is me - Update Profile)
| 2001 - present | Professor and Chief of Ophthalmology University of Toronto |
|---|---|
| 1993 - present | Director of Retinal Services University Health Network |
GLG Study Groups with Robert Devenyi, MD, FRCSC, FACS(?)
| Study Group Name | Members |
|---|---|
| Ophthalmologists | 1529 |
GLG NewsSM Analyses by Robert Devenyi, MD, FRCSC, FACS(?)
I agree...the present situation is really quite absurd...in most practices...IF a third party is willing to pay for Lucentis...patients usually get Lucentis...if patients have to pay themselves...they usually receive Avastin...despite there not being a shred of convincing evidence that Lucentis is superior...
-Retinal community unites against Genentech -both the American Association of Ophthalmology and the American Society of Retinal Specialists have condemned Genentech's actions -this represents profit-driven pharma at their worst -very poor decision by Genentech...not only to galvanize the profession...
Genentech should have voluntarily compared Lucentis with Avastin.All of Genentech's efforts to promote Lucentis seem self serving and insincere.
GLG InstituteSM Seminars with Robert Devenyi, MD, FRCSC, FACS(?)
View all GLG InstituteSM Seminars in Healthcare
Request a project with Robert Devenyi, MD, FRCSC, FACS
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms

